Accelerating Vaccine Development Through Community-Based Pharmacy Clinical Infrastructure
The partnership between WEP Clinical and RxE2 establishes a differentiated model for vaccine trial execution: one that leverages the accessibility of community pharmacies alongside global clinical operational expertise. As vaccine developers face increasing pressure to accelerate timelines while improving representation, this collaboration creates a scalable pathway to deliver trials closer to where patients live and receive care.
By integrating RxE2’s pharmacy-centered research network with WEP Clinical’s strategic, regulatory, and operational leadership, the partnership is designed to enhance efficiency, expand diversity, and maintain uncompromising quality across the clinical development lifecycle for vaccines.
Why This Model Matters
Legacy vaccine trials have traditionally relied on hospital systems or PCP practices, often creating barriers such as limited access, slower enrollment, and less representative populations. Community-based pharmacies represent one of the most trusted and frequently accessed healthcare settings in the country. Positioned at the intersection of convenience and clinical care, they offer a powerful opportunity to modernize clinical trials for the next vaccines.
The RxE2–WEP Clinical partnership operationalizes this opportunity, transforming pharmacies into high-quality clinical research environments supported by enterprise-grade infrastructure.
Partnership at a Glance
RxE2 Provides:
- A growing network of community pharmacies enabled for clinical research
- Expanded reach into underserved communities through generationally established trust
- Trusted healthcare touchpoints that drive engagement, participation, and retention
- Flexible, localized vaccine administration capabilities
- Accelerated recruitment potential through embedded community presence
WEP Clinical Provides:
- Global clinical operations and program management
- Strategic trial design aligned with real-world delivery models
- Regulatory guidance and inspection-ready quality frameworks
- Oversight, governance, and risk management
- Integrated patient services that support adherence and retention
Strategic Advantages
1. Faster Enrollment and Execution
Pharmacies operate at the front lines of preventative care, enabling rapid identification and enrollment of eligible participants while reducing site startup friction.
2. Meaningful Diversity
Community pharmacies naturally serve heterogeneous populations across demographic and socioeconomic segments, improving representation and strengthening the applicability of clinical data.
3. Patient-Centric Convenience
Participants benefit from familiar locations, extended hours, and reduced travel burden, factors proven to support recruitment and retention.
4. Quality Without Tradeoffs
Standardized processes, centralized oversight, and rigorous training ensure that decentralization does not equate to variability. Quality remains engineered into every layer of execution.
5. Scalable Infrastructure
The model allows sponsors to expand geographically without rebuilding operational frameworks, supporting both rapid studies and large-scale vaccine programs.
What This Means for Sponsors
Sponsors no longer need to view access, speed, and rigor as competing priorities.
Through this partnership, vaccine developers can:
- Activate research-capable pharmacy sites quickly
- Reach broader and more representative populations
- Generate high-quality, regulatory-ready date
- Reduce operational bottlenecks
- Execute trials with greater predictability
A Shared Vision
RxE2 and WEP Clinical are aligned around a clear ambition: Reimagining vaccine research by embedding clinical trials within the communities they are intended to protect.
This partnership reflects the next evolution of clinical development, leveraging decentralization intentionally to enhance access, execution, and patient reach.
For Partnership Inquiries:
Brian Tanner
Head of Clinical Strategy & Client Solutions
WEP Clinical
Email: [email protected]
Doug Liberi
Chief Commercial Officer
RxE2
Email: [email protected]